Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors

Abstract Objective Cancer-related lymphedema is a debilitating condition that adversely influences function, health and quality of life. The purpose of this study was to assess the prevalence, incidence, and risk factors of lower-limb lymphedema pre- through to 24 months post-surgery for gynecologic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2017-09, Vol.146 (3), p.623-629
Hauptverfasser: Hayes, Sandra C, Janda, Monika, Ward, Leigh C, Reul-Hirche, Hildegard, Steele, Megan L, Carter, Johnathan, Quinn, Michael, Cornish, Bruce, Obermair, Andreas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 629
container_issue 3
container_start_page 623
container_title Gynecologic oncology
container_volume 146
creator Hayes, Sandra C
Janda, Monika
Ward, Leigh C
Reul-Hirche, Hildegard
Steele, Megan L
Carter, Johnathan
Quinn, Michael
Cornish, Bruce
Obermair, Andreas
description Abstract Objective Cancer-related lymphedema is a debilitating condition that adversely influences function, health and quality of life. The purpose of this study was to assess the prevalence, incidence, and risk factors of lower-limb lymphedema pre- through to 24 months post-surgery for gynecological cancer. Methods A clinic-based sample of women (n = 408) with gynecological cancer participated in a prospective, longitudinal study (2008–2011) using self-reported measures (swelling in one or both legs) and objectively measured lymphedema (bioimpedance spectroscopy) at baseline (pre-surgery), six weeks–three months, 6–12 months, and 15–24 months post-surgery. Results At pre-surgery, 15% of women self-reported lymphedema and 27% had measurable evidence of lymphedema. By 24 months post-surgery, incidence of new self-reported or measured lymphedema was 45% and 37%, respectively. Three-quarters of these new cases presented by 12-months post-treatment. While lymphedema was transient for some women, 60% had persistent lymphedema. More extensive lymph node dissection, receipt of chemotherapy and radiation therapy, increasing body mass index, insufficient levels of physical activity, diagnosis of vulvar/vaginal cancer and presence of pre-treatment lymphedema were identified as potential risk factors (p < 0.05). Conclusion Findings support the need for integration of pre-surgical assessment, and prospective, post-treatment surveillance of lymphedema into gynecological cancer care. Future research exploring the role of maintaining healthy body weight, regular physical activity and education about early detection of lymphedema to improve gynecological cancer survivorship is warranted.
doi_str_mv 10.1016/j.ygyno.2017.06.004
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1911199335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825817308995</els_id><sourcerecordid>1911199335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-93adead19d2e121aeacdaf9010c28e3474550ba7a18845e3862934dbe51c661c3</originalsourceid><addsrcrecordid>eNqFUk2LFDEUbERxx9VfIEiOHrbHl6TT0xEUZPELBgQ_ziGTvJ7NbDoZk-6R_gv-atPO6sGLp7xAVT2q6lXVUwprCrR9cVjP-znENQO6WUO7BmjuVSsKUtRtJ-T9agUgoe6Y6C6qRzkfAIADZQ-rC9a1rKGiWVU_t_NwvEGLgyZ99D7-cGFPii6a6OPeGe2J0cFgekk-Y578mEmf4kA0OaaYj2hGd8Ir4mPYu3GyLiyEeBPTSHL5zySGgsST9lhUrogLxtllJDpYkly-Jb02Y0z5cfWg1z7jk7v3svr27u3X6w_19tP7j9dvtrURTIy15NqitlRahpRRjdpY3UugYFiHvNk0QsBObzTtukYgL1Ylb-wOBTVtSw2_rJ6fdYuB7xPmUQ0uG_ReB4xTVlRSSqXkXBQoP0NN8ZoT9uqY3KDTrCiopQR1UL9LUEsJClpVSiisZ3cLpt2A9i_nT-oF8OoMwGLz5DCpbNySiXWpBKpsdP9Z8PofvvEuLF3d4oz5EKdUaihOVGYK1JflDpYzoBsOnZSC_wLdLrGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1911199335</pqid></control><display><type>article</type><title>Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hayes, Sandra C ; Janda, Monika ; Ward, Leigh C ; Reul-Hirche, Hildegard ; Steele, Megan L ; Carter, Johnathan ; Quinn, Michael ; Cornish, Bruce ; Obermair, Andreas</creator><creatorcontrib>Hayes, Sandra C ; Janda, Monika ; Ward, Leigh C ; Reul-Hirche, Hildegard ; Steele, Megan L ; Carter, Johnathan ; Quinn, Michael ; Cornish, Bruce ; Obermair, Andreas</creatorcontrib><description>Abstract Objective Cancer-related lymphedema is a debilitating condition that adversely influences function, health and quality of life. The purpose of this study was to assess the prevalence, incidence, and risk factors of lower-limb lymphedema pre- through to 24 months post-surgery for gynecological cancer. Methods A clinic-based sample of women (n = 408) with gynecological cancer participated in a prospective, longitudinal study (2008–2011) using self-reported measures (swelling in one or both legs) and objectively measured lymphedema (bioimpedance spectroscopy) at baseline (pre-surgery), six weeks–three months, 6–12 months, and 15–24 months post-surgery. Results At pre-surgery, 15% of women self-reported lymphedema and 27% had measurable evidence of lymphedema. By 24 months post-surgery, incidence of new self-reported or measured lymphedema was 45% and 37%, respectively. Three-quarters of these new cases presented by 12-months post-treatment. While lymphedema was transient for some women, 60% had persistent lymphedema. More extensive lymph node dissection, receipt of chemotherapy and radiation therapy, increasing body mass index, insufficient levels of physical activity, diagnosis of vulvar/vaginal cancer and presence of pre-treatment lymphedema were identified as potential risk factors (p &lt; 0.05). Conclusion Findings support the need for integration of pre-surgical assessment, and prospective, post-treatment surveillance of lymphedema into gynecological cancer care. Future research exploring the role of maintaining healthy body weight, regular physical activity and education about early detection of lymphedema to improve gynecological cancer survivorship is warranted.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2017.06.004</identifier><identifier>PMID: 28624154</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Australia - epidemiology ; Body Mass Index ; Female ; Genital Neoplasms, Female - surgery ; Hematology, Oncology and Palliative Medicine ; Humans ; Incidence ; Longitudinal Studies ; Lower Extremity ; Lymph Node Excision - adverse effects ; Lymphedema - epidemiology ; Middle Aged ; Obstetrics and Gynecology ; Plethysmography, Impedance ; Postoperative Complications - epidemiology ; Postoperative Period ; Prevalence ; Prospective Studies ; Radiotherapy ; Risk Factors ; Sedentary Lifestyle ; Self Report ; Time Factors ; Vaginal Neoplasms - surgery ; Vulvar Neoplasms - surgery</subject><ispartof>Gynecologic oncology, 2017-09, Vol.146 (3), p.623-629</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-93adead19d2e121aeacdaf9010c28e3474550ba7a18845e3862934dbe51c661c3</citedby><cites>FETCH-LOGICAL-c525t-93adead19d2e121aeacdaf9010c28e3474550ba7a18845e3862934dbe51c661c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2017.06.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28624154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayes, Sandra C</creatorcontrib><creatorcontrib>Janda, Monika</creatorcontrib><creatorcontrib>Ward, Leigh C</creatorcontrib><creatorcontrib>Reul-Hirche, Hildegard</creatorcontrib><creatorcontrib>Steele, Megan L</creatorcontrib><creatorcontrib>Carter, Johnathan</creatorcontrib><creatorcontrib>Quinn, Michael</creatorcontrib><creatorcontrib>Cornish, Bruce</creatorcontrib><creatorcontrib>Obermair, Andreas</creatorcontrib><title>Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objective Cancer-related lymphedema is a debilitating condition that adversely influences function, health and quality of life. The purpose of this study was to assess the prevalence, incidence, and risk factors of lower-limb lymphedema pre- through to 24 months post-surgery for gynecological cancer. Methods A clinic-based sample of women (n = 408) with gynecological cancer participated in a prospective, longitudinal study (2008–2011) using self-reported measures (swelling in one or both legs) and objectively measured lymphedema (bioimpedance spectroscopy) at baseline (pre-surgery), six weeks–three months, 6–12 months, and 15–24 months post-surgery. Results At pre-surgery, 15% of women self-reported lymphedema and 27% had measurable evidence of lymphedema. By 24 months post-surgery, incidence of new self-reported or measured lymphedema was 45% and 37%, respectively. Three-quarters of these new cases presented by 12-months post-treatment. While lymphedema was transient for some women, 60% had persistent lymphedema. More extensive lymph node dissection, receipt of chemotherapy and radiation therapy, increasing body mass index, insufficient levels of physical activity, diagnosis of vulvar/vaginal cancer and presence of pre-treatment lymphedema were identified as potential risk factors (p &lt; 0.05). Conclusion Findings support the need for integration of pre-surgical assessment, and prospective, post-treatment surveillance of lymphedema into gynecological cancer care. Future research exploring the role of maintaining healthy body weight, regular physical activity and education about early detection of lymphedema to improve gynecological cancer survivorship is warranted.</description><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Australia - epidemiology</subject><subject>Body Mass Index</subject><subject>Female</subject><subject>Genital Neoplasms, Female - surgery</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Incidence</subject><subject>Longitudinal Studies</subject><subject>Lower Extremity</subject><subject>Lymph Node Excision - adverse effects</subject><subject>Lymphedema - epidemiology</subject><subject>Middle Aged</subject><subject>Obstetrics and Gynecology</subject><subject>Plethysmography, Impedance</subject><subject>Postoperative Complications - epidemiology</subject><subject>Postoperative Period</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Radiotherapy</subject><subject>Risk Factors</subject><subject>Sedentary Lifestyle</subject><subject>Self Report</subject><subject>Time Factors</subject><subject>Vaginal Neoplasms - surgery</subject><subject>Vulvar Neoplasms - surgery</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk2LFDEUbERxx9VfIEiOHrbHl6TT0xEUZPELBgQ_ziGTvJ7NbDoZk-6R_gv-atPO6sGLp7xAVT2q6lXVUwprCrR9cVjP-znENQO6WUO7BmjuVSsKUtRtJ-T9agUgoe6Y6C6qRzkfAIADZQ-rC9a1rKGiWVU_t_NwvEGLgyZ99D7-cGFPii6a6OPeGe2J0cFgekk-Y578mEmf4kA0OaaYj2hGd8Ir4mPYu3GyLiyEeBPTSHL5zySGgsST9lhUrogLxtllJDpYkly-Jb02Y0z5cfWg1z7jk7v3svr27u3X6w_19tP7j9dvtrURTIy15NqitlRahpRRjdpY3UugYFiHvNk0QsBObzTtukYgL1Ylb-wOBTVtSw2_rJ6fdYuB7xPmUQ0uG_ReB4xTVlRSSqXkXBQoP0NN8ZoT9uqY3KDTrCiopQR1UL9LUEsJClpVSiisZ3cLpt2A9i_nT-oF8OoMwGLz5DCpbNySiXWpBKpsdP9Z8PofvvEuLF3d4oz5EKdUaihOVGYK1JflDpYzoBsOnZSC_wLdLrGw</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Hayes, Sandra C</creator><creator>Janda, Monika</creator><creator>Ward, Leigh C</creator><creator>Reul-Hirche, Hildegard</creator><creator>Steele, Megan L</creator><creator>Carter, Johnathan</creator><creator>Quinn, Michael</creator><creator>Cornish, Bruce</creator><creator>Obermair, Andreas</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors</title><author>Hayes, Sandra C ; Janda, Monika ; Ward, Leigh C ; Reul-Hirche, Hildegard ; Steele, Megan L ; Carter, Johnathan ; Quinn, Michael ; Cornish, Bruce ; Obermair, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-93adead19d2e121aeacdaf9010c28e3474550ba7a18845e3862934dbe51c661c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Australia - epidemiology</topic><topic>Body Mass Index</topic><topic>Female</topic><topic>Genital Neoplasms, Female - surgery</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Incidence</topic><topic>Longitudinal Studies</topic><topic>Lower Extremity</topic><topic>Lymph Node Excision - adverse effects</topic><topic>Lymphedema - epidemiology</topic><topic>Middle Aged</topic><topic>Obstetrics and Gynecology</topic><topic>Plethysmography, Impedance</topic><topic>Postoperative Complications - epidemiology</topic><topic>Postoperative Period</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Radiotherapy</topic><topic>Risk Factors</topic><topic>Sedentary Lifestyle</topic><topic>Self Report</topic><topic>Time Factors</topic><topic>Vaginal Neoplasms - surgery</topic><topic>Vulvar Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayes, Sandra C</creatorcontrib><creatorcontrib>Janda, Monika</creatorcontrib><creatorcontrib>Ward, Leigh C</creatorcontrib><creatorcontrib>Reul-Hirche, Hildegard</creatorcontrib><creatorcontrib>Steele, Megan L</creatorcontrib><creatorcontrib>Carter, Johnathan</creatorcontrib><creatorcontrib>Quinn, Michael</creatorcontrib><creatorcontrib>Cornish, Bruce</creatorcontrib><creatorcontrib>Obermair, Andreas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayes, Sandra C</au><au>Janda, Monika</au><au>Ward, Leigh C</au><au>Reul-Hirche, Hildegard</au><au>Steele, Megan L</au><au>Carter, Johnathan</au><au>Quinn, Michael</au><au>Cornish, Bruce</au><au>Obermair, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>146</volume><issue>3</issue><spage>623</spage><epage>629</epage><pages>623-629</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objective Cancer-related lymphedema is a debilitating condition that adversely influences function, health and quality of life. The purpose of this study was to assess the prevalence, incidence, and risk factors of lower-limb lymphedema pre- through to 24 months post-surgery for gynecological cancer. Methods A clinic-based sample of women (n = 408) with gynecological cancer participated in a prospective, longitudinal study (2008–2011) using self-reported measures (swelling in one or both legs) and objectively measured lymphedema (bioimpedance spectroscopy) at baseline (pre-surgery), six weeks–three months, 6–12 months, and 15–24 months post-surgery. Results At pre-surgery, 15% of women self-reported lymphedema and 27% had measurable evidence of lymphedema. By 24 months post-surgery, incidence of new self-reported or measured lymphedema was 45% and 37%, respectively. Three-quarters of these new cases presented by 12-months post-treatment. While lymphedema was transient for some women, 60% had persistent lymphedema. More extensive lymph node dissection, receipt of chemotherapy and radiation therapy, increasing body mass index, insufficient levels of physical activity, diagnosis of vulvar/vaginal cancer and presence of pre-treatment lymphedema were identified as potential risk factors (p &lt; 0.05). Conclusion Findings support the need for integration of pre-surgical assessment, and prospective, post-treatment surveillance of lymphedema into gynecological cancer care. Future research exploring the role of maintaining healthy body weight, regular physical activity and education about early detection of lymphedema to improve gynecological cancer survivorship is warranted.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28624154</pmid><doi>10.1016/j.ygyno.2017.06.004</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2017-09, Vol.146 (3), p.623-629
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_1911199335
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Aged
Antineoplastic Agents - therapeutic use
Australia - epidemiology
Body Mass Index
Female
Genital Neoplasms, Female - surgery
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Longitudinal Studies
Lower Extremity
Lymph Node Excision - adverse effects
Lymphedema - epidemiology
Middle Aged
Obstetrics and Gynecology
Plethysmography, Impedance
Postoperative Complications - epidemiology
Postoperative Period
Prevalence
Prospective Studies
Radiotherapy
Risk Factors
Sedentary Lifestyle
Self Report
Time Factors
Vaginal Neoplasms - surgery
Vulvar Neoplasms - surgery
title Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A34%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lymphedema%20following%20gynecological%20cancer:%20Results%20from%20a%20prospective,%20longitudinal%20cohort%20study%20on%20prevalence,%20incidence%20and%20risk%20factors&rft.jtitle=Gynecologic%20oncology&rft.au=Hayes,%20Sandra%20C&rft.date=2017-09-01&rft.volume=146&rft.issue=3&rft.spage=623&rft.epage=629&rft.pages=623-629&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2017.06.004&rft_dat=%3Cproquest_cross%3E1911199335%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1911199335&rft_id=info:pmid/28624154&rft_els_id=S0090825817308995&rfr_iscdi=true